FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
Imaging Technology
JULY 24, 2024
mtaschetta-millane Wed, 07/24/2024 - 11:17 July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Through this NDA, Telix's objective is to further enhance patient access to PSMA-PET imaging and the clinical benefits of 68Ga imaging to underserved populations across the U.S., Accessed May 2024. [7]
Let's personalize your content